New York, New York (PRWEB) July 24, 2014
Plaintiffs in Canada have filed a testosterone lawsuit (http://www.drugbot.com/testosterone/lawsuit/) against the manufacturer of Delatestryl, alleging they were not adequately informed of the risks associated with the low testosterone injection, Bernstein Liebhard LLP reports. The class action complaint, which was filed in the Ontario Superior Court of Justice on July 22, 2014, further alleges that use of low testosterone therapy is associated with an increased risk of cardiovascular side-effects, including heart attack, stroke, deep vein thrombosis, pulmonary embolism, and death. (Court File No. 3704CP/14)
“Dozens of testosterone treatment lawsuits have already been filed in U.S. courts on behalf of men who allegedly experienced serious heart injuries due to this class of medication. We are not surprised that the litigation involving testosterone replacement therapy has spread to Canada,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating testosterone lawsuits on behalf of men who were allegedly harmed by these medications.
According to court documents, more than 150 testosterone lawsuits have been filed on behalf of U.S. plaintiffs in a multidistrict underway in U.S. District Court, Northern District of Illinois. Like the Canadian complaint, these cases also accuse the manufacturers of low testosterone therapies of failing to warn doctors and patients about their potential to cause serious heart problems. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)
Court records indicate that the U.S. testosterone litigation began to mount shortly after the Food & Drug Administration (FDA) announced that it was investigating cardiovascular risks associated with testosterone replacement therapy. According to an alert issued by the agency on January 31, 2014, the review was prompted by two studies which indicated that older men, as well as those with pre-existing heart disease, were more likely to suffer heart attacks, strokes or death if they were using testosterone medications.
According to a notice posted on the FDA’s website, the agency will convene a joint meeting of the Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on September 17, 2014, at which time the members will be asked to make recommendations pertaining to the cardiovascular side effects associated with the medications. The Committees will also address what factors should be considered when deciding whether men need to use low testosterone therapy.*
Victims of heart attacks, strokes, blood clots or other serious cardiovascular events allegedly associated with the use of testosterone replacement drugs may be eligible to file their own testosterone treatment lawsuit. To learn more, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.
*fda.gov/AdvisoryCommittees/Calendar/ucm404905.htm, FDA, July 17, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com